COMP <GO>
RARE vs ANIP // EV/EBITDA & P/E VALUATION
Ultragenyx Pharmaceutical Inc. (NASDAQ) VS. ANI Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: RARE 1
— ANIP 8
■ METRIC PARITY
LAST: $16.78 (-2.44%) • MKT CAP: $1.65B
valuation
—
LAST: $73.16 (+2.02%) • MKT CAP: $1.68B
valuation
13.7x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RARE VS. ANIP)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RARE | ANIP | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 16.00% | -51.00 | ANIP | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 13.7x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | 10.20% | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | 12.60% | -72.60 | ANIP | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 8.80% | -68.80 | ANIP | /net-margins <GO> |
| Revenue Growth (YoY) | 20.20% | 43.80% | -23.60 | ANIP | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.07% | -0.07 | ANIP | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 2.36 | -2.16 | ANIP | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 8/9 | -5.00 | ANIP | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 49.8 | 47.2 | +2.65 | RARE | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 18.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.65B | $1.68B | -$25.4M | ANIP | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RARE REV | ANIP REV | RARE GROSS % | ANIP GROSS % | RARE FCF | ANIP FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $673.0M | $883.4M | — | — | -$472.0M | $171.4M |
| FY 2024 | $560.0M | $614.4M | — | — | -$421.0M | $47.8M |
| FY 2023 | $434.0M | $486.8M | — | — | -$475.0M | $119.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RARE // BETA —
ANIP // BETA —